Cover; Contents; Acknowledgments; List of Abbreviations; Introduction; PART ONE: EVIDENCE; 1. The Generation of Evidence in Medicine: Evaluating the Benefits and Harms of Treatment; 2. The Use of Evidence: Federal Regulation of Prescription Drugs and Medical Devices; 3. The Subversion of Evidence: The Rosiglitazone Story; 4. Operate First, Evidence Later: The Special Case of Surgery; 5. Doctors and Evidence: Evidence-Based Medicine; PART TWO: POLITICS AND POLICY; Introduction; 6. Comparative Effectiveness Research: A New "Silver Bullet" for U.S. Health Care Costs
7. The Legislative Odyssey of Comparative Effectiveness Research: Birth in 2002 to the First Federal Mandate in 20038. 2005 to 2007: The Health Services Research Community Stirs, the "B" Word Awakens Policy Makers, and the House CHAMP Act Creates Divisions; 9. 2008 to 2010: The Baucus-Conrad Bills, the American Recovery and Reinvestment Act, and the Patient Protection and Affordable Care Act; 10. The Structure, Financing, and Processes of Federally Mandated Comparative Effectiveness Research and Why They Matter; PART THREE: INTERESTS; Introduction
11. Aligning Clinical Practice with Best Evidence of Comparative Effectiveness: Payment Policy for Evidence-Based Medical Care12. Dealing with Uncertainty: Payment Policy for the Generation of Evidence as Part of Clinical Practice; Epilogue; Index; A; B; C; D; E; F; G; H; I; J; K; L; M; N; O; P; R; S; T; U; V; W; X; Y; Z
Summary
'Comparative Effectiveness Research' provides the first complete account of how - and why - the federal government decided to make comparative effectiveness research (CER) an important feature of health reform and the Affordable Care Act of 2010
Notes
Includes index
Online resource; title from home page (viewed on July 24, 2013)
